BCAL Diagnostics Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Shane Ryan
Chief executive officer
AU$667.0k
Total compensation
| CEO salary percentage | 41.1% |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 3.7yrs |
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | AU$667k | AU$274k | -AU$6m |
Compensation vs Market: Shane's total compensation ($USD417.17K) is above average for companies of similar size in the Australian market ($USD291.28K).
Compensation vs Earnings: Insufficient data to compare Shane's compensation with company performance.
CEO
Shane Ryan
less than a year
Tenure
AU$667,016
Compensation
Mr. Shane Ryan, MBA is Chief Executive Officer of BCAL Diagnostics Limited from 2024. He joined the BCAL Diagnostics Limited on September 21, 2023. He was Chief Operating Officer of BCAL Diagnostics Limite...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 14.8yrs | AU$180.00k | 8.33% A$ 2.9m | |
| Co-Founder & Non-Executive Director | 14.8yrs | AU$54.67k | 7.08% A$ 2.4m | |
| Independent Non-Executive Director & Consultant | less than a year | AU$658.25k | 1.54% A$ 529.2k | |
| Independent Non-Executive Director | 3.4yrs | AU$54.67k | 0.40% A$ 139.2k | |
| Non-Executive Director | less than a year | AU$28.99k | 0.010% A$ 3.4k | |
| Independent Non-Executive Director | 4yrs | AU$59.00k | 1.48% A$ 509.1k |
3.7yrs
Average Tenure
Experienced Board: BDX's board of directors are considered experienced (3.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 07:00 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BCAL Diagnostics Limited is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Rosemary Cummins | MST Financial Services Pty Limited |